BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML
BioLineRx Ltd. (Nasdaq: BLRX) announced that the successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)